Emmessar Biotech & Nutrition Ltd (EMMESSA) reported revenue of ₹5.93 L and net profit of ₹13.15 L for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
EMMESSA fundamentals, Fundamental score 40/100
The statements below are read from Emmessar Biotech & Nutrition Ltd’s filed results, 1 filed quarter on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 7, 2026
Quarterly resultsConsolidated
₹ Cr
Jun2026Latest
YoYlatest
Sales
0.06
—
0.41
—
Operating profit
-0.35
—
OPM %
-594.9%
—
Other income
0.54
—
Interest
0.00
—
Depreciation
0.02
—
Profit before tax
0.16
—
Tax %
19.3%
—
Net profit
0.13
—
EPS (₹)
0.26
—
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±1.6%· EPS surprise: no estimates source
Q1'27filed Fri 7 Aug 14:12 · traded that sessiongap −2.0%close +1.0%
Q4'26filed Tue 12 May 14:58 · traded that sessiongap −1.0%close −1.4%
Q3'26filed Wed 11 Feb 14:28 · traded that sessiongap −0.5%close +2.2%
